Good Ventures awarded a grant of $5,300,000 over four years to Washington University to support research on Alzheimer’s disease by Professor Brendan Lucey, Professor David Holtzman, and colleagues. Professors Lucey and Holtzman will conduct a clinical trial on the impact of treatment with the sleep-inducing drug suvorexant on the progression of early-stage Alzheimer’s disease in humans. In a previous study on mice, Professor Holtzman found that a suvorexant-like treatment reduced the accumulation of amyloid plaques in the brain, a key indicator of Alzheimer’s disease. The professors’ findings may have important implications for Alzheimer’s treatment.
- Washington University
- Award Date:
- To support research on Alzheimer’s disease by Professor Brendan Lucey, Professor David Holtzman, and colleagues.